Journal Article
. 2013 Jun; 123(6):2447-63.
doi: 10.1172/JCI64859.

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

Aurélien Marabelle 1 Holbrook Kohrt  Idit Sagiv-Barfi  Bahareh Ajami  Robert C Axtell  Gang Zhou  Ranjani Rajapaksa  Michael R Green  James Torchia  Joshua Brody  Richard Luong  Michael D Rosenblum  Lawrence Steinman  Hyam I Levitsky  Victor Tse  Ronald Levy  
  • PMID: 23728179
  •     59 References
  •     169 citations


Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti-CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.

Immunological considerations of modern animal models of malignant primary brain tumors.
Michael E Sughrue, Isaac Yang, +4 authors, Andrew T Parsa.
J Transl Med, 2009 Oct 10; 7. PMID: 19814820    Free PMC article.
Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy.
A T Parsa, I Chakrabarti, +4 authors, J N Bruce.
Neurosurgery, 2000 Oct 03; 47(4). PMID: 11014444
Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye.
Br J Exp Pathol, 1948 Feb 01; 29(1). PMID: 18865105    Free PMC article.
Highly Cited.
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE.
Andrea Reboldi, Caroline Coisne, +7 authors, Federica Sallusto.
Nat Immunol, 2009 Mar 24; 10(5). PMID: 19305396
Highly Cited.
Regulatory T cells in cancer.
Marc Beyer, Joachim L Schultze.
Blood, 2006 Jul 25; 108(3). PMID: 16861339
Highly Cited. Review.
Differences in tumor regulatory T-cell localization and activation status impact patient outcome.
Christine Ménétrier-Caux, Michael Gobert, Christophe Caux.
Cancer Res, 2009 Oct 08; 69(20). PMID: 19808962
Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance.
Xuefang Cao, Karen Leonard, +7 authors, Timothy J Ley.
Cancer Res, 2009 Oct 22; 69(22). PMID: 19843867    Free PMC article.
Interleukin-12 converts Foxp3+ regulatory T cells to interferon-γ-producing Foxp3+ T cells that inhibit colitis.
Ting Feng, Anthony T Cao, +2 authors, Yingzi Cong.
Gastroenterology, 2011 Mar 23; 140(7). PMID: 21419767    Free PMC article.
TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40.
Ryoko Hamano, Jiaqiang Huang, +2 authors, Xin Chen.
Eur J Immunol, 2011 Apr 15; 41(7). PMID: 21491419    Free PMC article.
Split immunity: immune inhibition of rat gliomas by subcutaneous exposure to unmodified live tumor cells.
Ilan Volovitz, Yotvat Marmor, +7 authors, Lea Eisenbach.
J Immunol, 2011 Oct 15; 187(10). PMID: 21998458
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.
C L Bennett, J Christie, +7 authors, H D Ochs.
Nat Genet, 2001 Jan 04; 27(1). PMID: 11137993
Highly Cited.
IL-12 is required for anti-OX40-mediated CD4 T cell survival.
Carl E Ruby, Ryan Montler, +2 authors, Andrew D Weinberg.
J Immunol, 2008 Feb 06; 180(4). PMID: 18250420
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Immunostimulatory monoclonal antibodies for cancer therapy.
Ignacio Melero, Sandra Hervas-Stubbs, +2 authors, Lieping Chen.
Nat Rev Cancer, 2007 Jan 26; 7(2). PMID: 17251916
Highly Cited. Review.
Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself.
Jiali Li, Wenru Song, +5 authors, Ronald Levy.
J Immunol, 2007 Aug 07; 179(4). PMID: 17675511
Phase I/II study of ipilimumab for patients with metastatic melanoma.
Jeffrey S Weber, Steven O'Day, +5 authors, Evan Hersh.
J Clin Oncol, 2008 Nov 20; 26(36). PMID: 19018089
Highly Cited.
Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
F M Sirotnak, D M Moccio, D M Dorick.
Cancer Res, 1978 Feb 01; 38(2). PMID: 304375
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
S J O'Day, M Maio, +13 authors, J D Wolchok.
Ann Oncol, 2010 Feb 12; 21(8). PMID: 20147741
Highly Cited.
Control of immunity by the TNFR-related molecule OX40 (CD134).
Michael Croft.
Annu Rev Immunol, 2010 Mar 24; 28. PMID: 20307208    Free PMC article.
Highly Cited. Review.
OX40 costimulation turns off Foxp3+ Tregs.
Minh Diem Vu, Xiang Xiao, +6 authors, Xian Chang Li.
Blood, 2007 Jun 19; 110(7). PMID: 17575071    Free PMC article.
Highly Cited.
Mouse 4T1 breast tumor model.
B A Pulaski, S Ostrand-Rosenberg.
Curr Protoc Immunol, 2008 Apr 25; Chapter 20. PMID: 18432775
Highly Cited.
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
Jeffrey Weber, John A Thompson, +9 authors, Steven J O'Day.
Clin Cancer Res, 2009 Aug 13; 15(17). PMID: 19671877
Highly Cited.
Firefly luciferase-based dynamic bioluminescence imaging: a noninvasive technique to assess tumor angiogenesis.
Amy Sun, Lewis Hou, +5 authors, Victor Tse.
Neurosurgery, 2010 Mar 23; 66(4). PMID: 20305496    Free PMC article.
Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.
Mario P Colombo, Silvia Piconese.
Nat Rev Cancer, 2007 Oct 25; 7(11). PMID: 17957190
Highly Cited. Review.
Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells.
Xin Chen, Monika Bäumel, +2 authors, Joost J Oppenheim.
J Immunol, 2007 Jun 21; 179(1). PMID: 17579033
Highly Cited.
Targeting regulatory T cells in cancer.
William L Byrne, Kingston H G Mills, James A Lederer, Gerald C O'Sullivan.
Cancer Res, 2011 Nov 10; 71(22). PMID: 22068034    Free PMC article.
Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees.
Bindu Varghese, Adam Widman, +5 authors, Ronald Levy.
Blood, 2009 Sep 19; 114(20). PMID: 19762487    Free PMC article.
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.
Roch Houot, Ronald Levy.
Blood, 2008 Oct 23; 113(15). PMID: 18941113    Free PMC article.
CTLA-4 control over Foxp3+ regulatory T cell function.
Kajsa Wing, Yasushi Onishi, +5 authors, Shimon Sakaguchi.
Science, 2008 Oct 11; 322(5899). PMID: 18845758
Highly Cited.
Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse.
M E Brunkow, E W Jeffery, +7 authors, F Ramsdell.
Nat Genet, 2001 Jan 04; 27(1). PMID: 11138001
Highly Cited.
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.
Gang Zhou, Zhengbin Lu, +2 authors, Aimee L Marson.
J Exp Med, 2004 Dec 15; 200(12). PMID: 15596524    Free PMC article.
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.
Anna Maria Di Giacomo, Maurizio Biagioli, Michele Maio.
Semin Oncol, 2010 Nov 16; 37(5). PMID: 21074065
T-regulatory cell modulation: the future of cancer immunotherapy?
S Nizar, J Copier, +4 authors, A Dalgleish.
Br J Cancer, 2009 Apr 23; 100(11). PMID: 19384299    Free PMC article.
Successful treatment of melanoma brain metastases with adoptive cell therapy.
Jenny J Hong, Steven A Rosenberg, +4 authors, Richard M Sherry.
Clin Cancer Res, 2010 Aug 20; 16(19). PMID: 20719934    Free PMC article.
Cancer immunotherapy--the endgame begins.
Louis M Weiner.
N Engl J Med, 2008 Jun 21; 358(25). PMID: 18565858    Free PMC article.
Trafficking of immune cells in the central nervous system.
Emma H Wilson, Wolfgang Weninger, Christopher A Hunter.
J Clin Invest, 2010 May 05; 120(5). PMID: 20440079    Free PMC article.
Highly Cited. Review.
The reverse stop-signal model for CTLA4 function.
Christopher E Rudd.
Nat Rev Immunol, 2008 Jan 26; 8(2). PMID: 18219311
Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors.
J J Tzeng, R F Barth, C G Orosz, S M James.
Cancer Res, 1991 May 01; 51(9). PMID: 2015600
X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy.
R S Wildin, F Ramsdell, +13 authors, M E Brunkow.
Nat Genet, 2001 Jan 04; 27(1). PMID: 11137992
Highly Cited.
Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype.
Zhi-Chun Ding, Bruce R Blazar, +2 authors, Gang Zhou.
Blood, 2010 Feb 02; 115(12). PMID: 20118405    Free PMC article.
Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease.
Margarita Dominguez-Villar, Clare M Baecher-Allan, David A Hafler.
Nat Med, 2011 May 05; 17(6). PMID: 21540856    Free PMC article.
Highly Cited.
Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments.
Tsipi Shoham, Ranjani Rajapaksa, +2 authors, Shoshana Levy.
Mol Cell Biol, 2006 Feb 02; 26(4). PMID: 16449649    Free PMC article.
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
Jedd D Wolchok, Bart Neyns, +14 authors, Celeste Lebbé.
Lancet Oncol, 2009 Dec 17; 11(2). PMID: 20004617
Highly Cited.
FOXP3 defines regulatory T cells in human tumor and autoimmune disease.
Ilona Kryczek, Rebecca Liu, +11 authors, Weiping Zou.
Cancer Res, 2009 Apr 23; 69(9). PMID: 19383912
Cancer immunotherapy comes of age.
Ira Mellman, George Coukos, Glenn Dranoff.
Nature, 2011 Dec 24; 480(7378). PMID: 22193102    Free PMC article.
Highly Cited. Review.
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Sergio A Quezada, Karl S Peggs, Michael A Curran, James P Allison.
J Clin Invest, 2006 Jun 17; 116(7). PMID: 16778987    Free PMC article.
Highly Cited.
Regulatory T cells, tumour immunity and immunotherapy.
Weiping Zou.
Nat Rev Immunol, 2006 Mar 25; 6(4). PMID: 16557261
Highly Cited. Review.
Chemotherapy delivery issues in central nervous system malignancy: a reality check.
Leslie L Muldoon, Carole Soussain, +8 authors, Edward A Neuwelt.
J Clin Oncol, 2007 Jun 01; 25(16). PMID: 17538176
Highly Cited. Review.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system.
J D Sedgwick, S Schwender, +3 authors, V ter Meulen.
Proc Natl Acad Sci U S A, 1991 Aug 15; 88(16). PMID: 1651506    Free PMC article.
Highly Cited.
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
Mojgan Ahmadzadeh, Steven A Rosenberg.
Blood, 2005 Nov 24; 107(6). PMID: 16304057    Free PMC article.
Highly Cited.
Checkpoint blockade in cancer immunotherapy.
Alan J Korman, Karl S Peggs, James P Allison.
Adv Immunol, 2006 May 30; 90. PMID: 16730267    Free PMC article.
Highly Cited. Review.
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
Joshua D Brody, Weiyun Z Ai, +10 authors, Ronald Levy.
J Clin Oncol, 2010 Aug 11; 28(28). PMID: 20697067    Free PMC article.
Highly Cited.
Tregs and rethinking cancer immunotherapy.
Tyler J Curiel.
J Clin Invest, 2007 May 04; 117(5). PMID: 17476346    Free PMC article.
Highly Cited. Review.
Regulatory T cell lineage specification by the forkhead transcription factor foxp3.
Jason D Fontenot, Jeffrey P Rasmussen, +3 authors, Alexander Y Rudensky.
Immunity, 2005 Mar 23; 22(3). PMID: 15780990
Highly Cited.
TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function.
Meital Nagar, Jasmine Jacob-Hirsch, +7 authors, Itamar Goldstein.
J Immunol, 2010 Feb 26; 184(7). PMID: 20181891
Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.
Lois A Lampson.
MAbs, 2010 Dec 15; 3(2). PMID: 21150307    Free PMC article.
Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
J Kjaergaard, J Tanaka, +3 authors, S Shu.
Cancer Res, 2000 Oct 18; 60(19). PMID: 11034096
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Targeting immunosuppression for cancer therapy.
Cristina Ghirelli, Thorsten Hagemann.
J Clin Invest, 2013 Jun 04; 123(6). PMID: 23728169    Free PMC article.
Tumour immunology: cracking the combination.
Yvonne Bordon.
Nat Rev Immunol, 2013 Jun 08; 13(7). PMID: 23743478
Anticancer drugs: Cracking the combination.
Yvonne Bordon.
Nat Rev Drug Discov, 2013 Jul 03; 12(7). PMID: 23812266
Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.
Aurélien Marabelle, Holbrook Kohrt, Ronald Levy.
Clin Cancer Res, 2013 Aug 24; 19(19). PMID: 23965900    Free PMC article.
Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.
Christel Devaud, Jennifer A Westwood, +13 authors, Michael H Kershaw.
Mol Ther, 2013 Sep 21; 22(1). PMID: 24048441    Free PMC article.
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu.
Andre Kunert, Trudy Straetemans, +4 authors, Reno Debets.
Front Immunol, 2013 Nov 23; 4. PMID: 24265631    Free PMC article.
T cell responses: naive to memory and everything in between.
Nathan D Pennock, Jason T White, +3 authors, Ross M Kedl.
Adv Physiol Educ, 2013 Dec 03; 37(4). PMID: 24292902    Free PMC article.
Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity.
Christian Perez-Shibayama, Cristina Gil-Cruz, +4 authors, Burkhard Ludewig.
PLoS One, 2013 Dec 07; 8(11). PMID: 24312302    Free PMC article.
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
Jason R Westin, Fuliang Chu, +19 authors, Sattva S Neelapu.
Lancet Oncol, 2013 Dec 18; 15(1). PMID: 24332512    Free PMC article.
Highly Cited.
Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.
Franz Buchegger, Steven M Larson, +6 authors, Daniel E Speiser.
Clin Dev Immunol, 2013 Dec 29; 2013. PMID: 24371449    Free PMC article.
Intraperitoneal prophylaxis with CpG oligodeoxynucleotides protects neutropenic mice against intracerebral Escherichia coli K1 infection.
Sandra Ribes, Tanja Meister, +5 authors, Roland Nau.
J Neuroinflammation, 2014 Jan 25; 11. PMID: 24456653    Free PMC article.
Local immunomodulation for cancer therapy: Providing treatment where needed.
Marieke F Fransen, Ferry Ossendorp, Ramon Arens, Cornelis Jm Melief.
Oncoimmunology, 2014 Feb 04; 2(11). PMID: 24490127    Free PMC article.
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
Deepak Mittal, Matthew M Gubin, Robert D Schreiber, Mark J Smyth.
Curr Opin Immunol, 2014 Feb 18; 27. PMID: 24531241    Free PMC article.
Highly Cited. Review.
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
Dmitriy Zamarin, Rikke B Holmgaard, +6 authors, James P Allison.
Sci Transl Med, 2014 Mar 07; 6(226). PMID: 24598590    Free PMC article.
Highly Cited.
Intratumoral immunization: a new paradigm for cancer therapy.
Aurélien Marabelle, Holbrook Kohrt, Christophe Caux, Ronald Levy.
Clin Cancer Res, 2014 Apr 03; 20(7). PMID: 24691639    Free PMC article.
Highly Cited.
A brief personal history of cancer immunotherapy at Stanford: if these walls could talk….
Ron Levy.
Immunol Res, 2014 Apr 25; 58(2-3). PMID: 24760220
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Ole Audun Werner Haabeth, Anders Aune Tveita, +8 authors, Bjarne Bogen.
Front Immunol, 2014 May 02; 5. PMID: 24782871    Free PMC article.
Highly Cited. Review.
The early history of Stanford Immunology.
Patricia P Jones, Leonore A Herzenberg.
Immunol Res, 2014 May 09; 58(2-3). PMID: 24804901
Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression.
Lora C Bailey-Downs, Jessica E Thorpe, +6 authors, Michael A Ihnat.
PLoS One, 2014 Jun 01; 9(5). PMID: 24878664    Free PMC article.
The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.
Delia Nelson, Scott Fisher, Bruce Robinson.
J Immunol Res, 2014 Jun 24; 2014. PMID: 24955376    Free PMC article.
Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts.
Stefanie N Linch, William L Redmond.
Oncoimmunology, 2014 Jul 23; 3. PMID: 25050194    Free PMC article.
Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs.
Leah Alabanza, Sacha Gnjatic, Nina Bhardwaj, Joshua Brody.
Oncoimmunology, 2014 Oct 24; 3. PMID: 25339995    Free PMC article.
Immunomodulatory antibody therapy of cancer: the closer, the better.
Roxana S Dronca, Haidong Dong.
Clin Cancer Res, 2014 Oct 30; 21(5). PMID: 25351746    Free PMC article.
Current clinical trials testing combinations of immunotherapy and radiation.
Marka Crittenden, Holbrook Kohrt, +5 authors, Silvia Formenti.
Semin Radiat Oncol, 2014 Dec 08; 25(1). PMID: 25481267    Free PMC article.
Highly Cited. Review.
The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
Andrea Khong, Amanda L Cleaver, +8 authors, Bruce W Robinson.
BMC Cancer, 2014 Dec 19; 14. PMID: 25518732    Free PMC article.
New insights into the mechanism of action of immune checkpoint antibodies.
Aurélien Marabelle, Holbrook Kohrt, Ronald Levy.
Oncoimmunology, 2015 Jan 23; 3(8). PMID: 25610751    Free PMC article.
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.
Idit Sagiv-Barfi, Holbrook E Kohrt, +2 authors, Ronald Levy.
Blood, 2015 Feb 11; 125(13). PMID: 25662332    Free PMC article.
Targeting the tumor microenvironment to enhance antitumor immune responses.
Kevin Van der Jeught, Lukasz Bialkowski, +7 authors, Karine Breckpot.
Oncotarget, 2015 Feb 16; 6(3). PMID: 25682197    Free PMC article.
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.
Stefanie N Linch, Michael J McNamara, William L Redmond.
Front Oncol, 2015 Mar 13; 5. PMID: 25763356    Free PMC article.
Highly Cited. Review.
Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.
Kenneth S Rosenthal, Katalin Mikecz, +4 authors, Daniel H Zimmerman.
Expert Rev Vaccines, 2015 Mar 20; 14(6). PMID: 25787143    Free PMC article.
Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy.
Hiromi Kumon, Katsumi Sasaki, +7 authors, Yasutomo Nasu.
Clin Med Insights Oncol, 2015 Apr 11; 9. PMID: 25861236    Free PMC article.
Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine.
Kazuhide Sato, Takahito Nakajima, Peter L Choyke, Hisataka Kobayashi.
RSC Adv, 2015 Apr 14; 5(32). PMID: 25866624    Free PMC article.
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
Atsushi Yonezawa, Suparna Dutt, +2 authors, Holbrook E Kohrt.
Clin Cancer Res, 2015 Apr 25; 21(14). PMID: 25908780    Free PMC article.
Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response.
Xiaojun Xia, Junhua Mai, +13 authors, Haifa Shen.
Cell Rep, 2015 May 06; 11(6). PMID: 25937283    Free PMC article.
6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.
Laura Jeanbart, Iraklis C Kourtis, +2 authors, Jeffrey A Hubbell.
Cancer Immunol Immunother, 2015 May 20; 64(8). PMID: 25982370    Free PMC article.
Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma.
Saleh Rachidi, Kristin Wallace, +3 authors, Zihai Li.
Head Neck, 2015 Jun 05; 38 Suppl 1. PMID: 26040762    Free PMC article.
In-situ tumor vaccination: Bringing the fight to the tumor.
Robert H Pierce, Jean S Campbell, +2 authors, Holbrook E K Kohrt.
Hum Vaccin Immunother, 2015 Jun 10; 11(8). PMID: 26055074    Free PMC article.
Ubiquitin-dependent regulation of Foxp3 and Treg function.
Joseph Barbi, Drew M Pardoll, Fan Pan.
Immunol Rev, 2015 Jun 19; 266(1). PMID: 26085205    Free PMC article.
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Aitziber Buqué, Norma Bloy, +12 authors, Lorenzo Galluzzi.
Oncoimmunology, 2015 Jul 03; 4(4). PMID: 26137403    Free PMC article.
"In situ" vaccination for systemic effects in follicular lymphoma.
Arne Kolstad, Johanna Olweus.
Oncoimmunology, 2015 Jul 04; 4(7). PMID: 26140239    Free PMC article.
Engineering New Approaches to Cancer Vaccines.
Naveen K Mehta, Kelly D Moynihan, Darrell J Irvine.
Cancer Immunol Res, 2015 Jul 15; 3(8). PMID: 26156157    Free PMC article.
Big opportunities for small molecules in immuno-oncology.
Jerry L Adams, James Smothers, Roopa Srinivasan, Axel Hoos.
Nat Rev Drug Discov, 2015 Aug 01; 14(9). PMID: 26228631
Highly Cited. Review.
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.
Nikhil S Joshi, Elliot H Akama-Garren, +11 authors, Tyler Jacks.
Immunity, 2015 Sep 06; 43(3). PMID: 26341400    Free PMC article.
Highly Cited.
A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.
Meihua Chen, Rong Xiang, +14 authors, Yuquan Wei.
Sci Rep, 2015 Sep 24; 5. PMID: 26394925    Free PMC article.
Targeting the tumor niche to treat cancer.
Sattva S Neelapu, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2015 Oct 10; 112(42). PMID: 26450879    Free PMC article.
Cancer immunotherapy: Strategies for personalization and combinatorial approaches.
Vishwanath Sathyanarayanan, Sattva S Neelapu.
Mol Oncol, 2015 Nov 10; 9(10). PMID: 26548534    Free PMC article.
Combination cancer immunotherapies tailored to the tumour microenvironment.
Mark J Smyth, Shin Foong Ngiow, Antoni Ribas, Michele W L Teng.
Nat Rev Clin Oncol, 2015 Nov 26; 13(3). PMID: 26598942
Highly Cited. Review.
In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.
Linda Hammerich, Adam Binder, Joshua D Brody.
Mol Oncol, 2015 Dec 04; 9(10). PMID: 26632446    Free PMC article.
Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
Qifang Zhang, Dewan Md Sakib Hossain, +13 authors, Marcin Kortylewski.
Blood, 2016 Jan 23; 127(13). PMID: 26796361    Free PMC article.
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Joseph M Ryan, Jeffrey S Wasser, Adam J Adler, Anthony T Vella.
Expert Opin Biol Ther, 2016 Feb 09; 16(5). PMID: 26855028    Free PMC article.
Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models.
Julie K Jang, Leslie A Khawli, +6 authors, Alan L Epstein.
Cancer Immunol Immunother, 2016 Mar 11; 65(5). PMID: 26960932    Free PMC article.
Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.
Arta M Monjazeb, Michael S Kent, +13 authors, William J Murphy.
Clin Cancer Res, 2016 Mar 17; 22(17). PMID: 26979392    Free PMC article.
OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.
Chester Lai, Suzannah August, +9 authors, Eugene Healy.
Clin Cancer Res, 2016 Apr 02; 22(16). PMID: 27034329    Free PMC article.
The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.
T Yamazaki, J M Pitt, +5 authors, L Zitvogel.
Cell Death Differ, 2016 Apr 16; 23(6). PMID: 27082453    Free PMC article.
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.
Dmitriy Zamarin, Jedd D Wolchok.
Mol Ther Oncolytics, 2014 Jan 01; 1. PMID: 27119094    Free PMC article.
Strategies for designing synthetic immune agonists.
Tom Y-H Wu.
Immunology, 2016 May 24; 148(4). PMID: 27213842    Free PMC article.
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.
Kipp Weiskopf, Nadine S Jahchan, +31 authors, Julien Sage.
J Clin Invest, 2016 Jun 14; 126(7). PMID: 27294525    Free PMC article.
Highly Cited.
CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Zhenhua Ren, Jingya Guo, +7 authors, Yang-Xin Fu.
Clin Cancer Res, 2016 Jun 30; 23(1). PMID: 27354469    Free PMC article.
Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody.
Chao Wang, Wujin Sun, +2 authors, Zhen Gu.
Adv Mater, 2016 Oct 21; 28(40). PMID: 27558441    Free PMC article.
CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1.
Peng Yin, Xin Liu, +4 authors, Haidong Dong.
Oncotarget, 2016 Sep 08; 7(43). PMID: 27602959    Free PMC article.
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.
Roch Houot, Philippe Gaulard, +18 authors, Daniel Olive.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622041    Free PMC article.
Nutrients and the microenvironment to feed a T cell army.
Marc O Johnson, Peter J Siska, Diana C Contreras, Jeffrey C Rathmell.
Semin Immunol, 2016 Oct 08; 28(5). PMID: 27712958    Free PMC article.
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.
Peter Ellmark, Sara M Mangsbo, +2 authors, Thomas H Tötterman.
Cancer Immunol Immunother, 2016 Oct 08; 66(1). PMID: 27714433    Free PMC article.
Understanding Immune Cells in Tertiary Lymphoid Organ Development: It Is All Starting to Come Together.
Gareth W Jones, David G Hill, Simon A Jones.
Front Immunol, 2016 Oct 19; 7. PMID: 27752256    Free PMC article.
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.
Marco De Simone, Alberto Arrigoni, +28 authors, Massimiliano Pagani.
Immunity, 2016 Nov 17; 45(5). PMID: 27851914    Free PMC article.
Highly Cited.
Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma.
João Paulo Portela Catani, Ruan F V Medrano, +6 authors, Bryan E Strauss.
Transl Oncol, 2016 Dec 06; 9(6). PMID: 27916291    Free PMC article.
TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo.
Jing Wu, Shuang Li, +5 authors, Jingtao Chen.
Oncotarget, 2017 Jan 05; 8(7). PMID: 28052019    Free PMC article.
Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Alexander L Rakhmilevich, Mildred Felder, +8 authors, Paul M Sondel.
J Immunol, 2017 Jan 08; 198(4). PMID: 28062694    Free PMC article.
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
Franck Carbonnel, Emilie Soularue, +4 authors, Caroline Robert.
Semin Immunopathol, 2017 Jan 18; 39(3). PMID: 28093620
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
Xiaoyan Feng, Li Zhang, +6 authors, Kenneth C Anderson.
Clin Cancer Res, 2017 Mar 03; 23(15). PMID: 28249894    Free PMC article.
Highly Cited.
Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols.
Matthew T Silvestrini, Elizabeth S Ingham, +12 authors, Katherine W Ferrara.
JCI Insight, 2017 Mar 30; 2(6). PMID: 28352658    Free PMC article.
Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis.
Desislava Tsoneva, Boris Minev, +3 authors, Aladar A Szalay.
Mol Ther Oncolytics, 2017 May 10; 5. PMID: 28480327    Free PMC article.
Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.
Dong Sun Oh, Heegon Kim, +4 authors, Heung Kyu Lee.
Oncotarget, 2017 May 26; 8(29). PMID: 28537894    Free PMC article.
Delivering safer immunotherapies for cancer.
Lauren Milling, Yuan Zhang, Darrell J Irvine.
Adv Drug Deliv Rev, 2017 May 27; 114. PMID: 28545888    Free PMC article.
Highly Cited. Review.
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Casey R Ager, Matthew J Reilley, +3 authors, Michael A Curran.
Cancer Immunol Res, 2017 Jul 05; 5(8). PMID: 28674082    Free PMC article.
Highly Cited.
TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.
Timothy Nj Bullock.
Curr Opin Immunol, 2017 Jul 28; 47. PMID: 28750279    Free PMC article.
Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells.
Melanie L Grant, Nicholas Shields, +5 authors, Sarah L Young.
Clin Transl Immunology, 2017 Aug 10; 6(7). PMID: 28791124    Free PMC article.
Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.
Ece Esin.
Biomed Res Int, 2017 Aug 30; 2017. PMID: 28848761    Free PMC article.
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
David J Messenheimer, Shawn M Jensen, +6 authors, Bernard A Fox.
Clin Cancer Res, 2017 Sep 01; 23(20). PMID: 28855348    Free PMC article.
Highly Cited.
Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF.
Andrea J Manrique-Rincón, Camila M Beraldo, Jessica M Toscaro, Marcio C Bajgelman.
Front Immunol, 2017 Oct 05; 8. PMID: 28974950    Free PMC article.
STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.
Qiuju Han, Yaqun Wang, Min Pang, Jian Zhang.
J Exp Clin Cancer Res, 2017 Nov 09; 36(1). PMID: 29115974    Free PMC article.
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.
Manisha Singh, Christina Vianden, +15 authors, Willem W Overwijk.
Nat Commun, 2017 Nov 14; 8(1). PMID: 29129918    Free PMC article.
Advances in immunotherapeutic research for glioma therapy.
Jeremy Tetsuo Miyauchi, Stella E Tsirka.
J Neurol, 2017 Dec 07; 265(4). PMID: 29209782    Free PMC article.
The Future of Immunotherapy: A 20-Year Perspective.
David C Wraith.
Front Immunol, 2017 Dec 14; 8. PMID: 29234325    Free PMC article.
Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.
Luigi Cari, Giuseppe Nocentini, Graziella Migliorati, Carlo Riccardi.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308313    Free PMC article.
Eradication of spontaneous malignancy by local immunotherapy.
Idit Sagiv-Barfi, Debra K Czerwinski, +4 authors, Ronald Levy.
Sci Transl Med, 2018 Feb 02; 10(426). PMID: 29386357    Free PMC article.
Highly Cited.
Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.
Anna H Turaj, Kerry L Cox, +10 authors, Sean H Lim.
Sci Rep, 2018 Feb 06; 8(1). PMID: 29396470    Free PMC article.
Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models.
Grammatiki Fotaki, Chuan Jin, +5 authors, Magnus Essand.
Oncoimmunology, 2018 Feb 06; 7(3). PMID: 29399398    Free PMC article.
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.
Anje Cauwels, Sandra Van Lint, +11 authors, Jan Tavernier.
Oncoimmunology, 2018 Feb 06; 7(3). PMID: 29399401    Free PMC article.
B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
Xingli Zhao, Zhuoran Zhang, +11 authors, Marcin Kortylewski.
Mol Ther, 2018 Feb 13; 26(3). PMID: 29433938    Free PMC article.
Using immunotherapy to boost the abscopal effect.
Wilfred Ngwa, Omoruyi Credit Irabor, +3 authors, Silvia C Formenti.
Nat Rev Cancer, 2018 Feb 17; 18(5). PMID: 29449659    Free PMC article.
Highly Cited. Review.
Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.
Yawara Kawano, Oksana Zavidij, +24 authors, Irene M Ghobrial.
J Clin Invest, 2018 Mar 21; 128(6). PMID: 29558366    Free PMC article.
Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy.
Jonathan Pol, Guido Kroemer.
Cell Res, 2018 Mar 30; 28(5). PMID: 29593340    Free PMC article.
Imaging activated T cells predicts response to cancer vaccines.
Israt S Alam, Aaron T Mayer, +7 authors, Sanjiv S Gambhir.
J Clin Invest, 2018 Mar 30; 128(6). PMID: 29596062    Free PMC article.
Highly Cited.
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
Randi B Gombos, Ana Gonzalez, +24 authors, Nicholas S Wilson.
PLoS One, 2018 Apr 05; 13(4). PMID: 29617360    Free PMC article.
CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols.
Jai Woong Seo, Richard Tavaré, +7 authors, Katherine W Ferrara.
Clin Cancer Res, 2018 Jul 04; 24(20). PMID: 29967252    Free PMC article.
Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation.
Michael Chavez, Matthew T Silvestrini, +11 authors, Katherine W Ferrara.
Theranostics, 2018 Jul 22; 8(13). PMID: 30026870    Free PMC article.
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.
Matthew J Frank, Patrick M Reagan, +9 authors, Ronald Levy.
Cancer Discov, 2018 Aug 30; 8(10). PMID: 30154192    Free PMC article.
A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Prabhakaran Kumar, Palash Bhattacharya, Bellur S Prabhakar.
J Autoimmun, 2018 Sep 04; 95. PMID: 30174217    Free PMC article.
Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide.
Marco C Merlano, Anna M Merlotti, +9 authors, Renzo Corvò.
Clin Transl Radiat Oncol, 2018 Sep 07; 12. PMID: 30186977    Free PMC article.
mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice.
Ole A W Haabeth, Timothy R Blake, +3 authors, Ronald Levy.
Proc Natl Acad Sci U S A, 2018 Sep 12; 115(39). PMID: 30201728    Free PMC article.
Combination immune checkpoint blockade as an effective therapy for mesothelioma.
Vanessa S Fear, Caitlin Tilsed, +10 authors, Scott A Fisher.
Oncoimmunology, 2018 Oct 06; 7(10). PMID: 30288361    Free PMC article.
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
David A Knorr, Rony Dahan, Jeffrey V Ravetch.
Proc Natl Acad Sci U S A, 2018 Oct 10; 115(43). PMID: 30297432    Free PMC article.
Effects of tumor metabolic microenvironment on regulatory T cells.
Yi-An Wang, Xiao-Ling Li, +13 authors, Wei Xiong.
Mol Cancer, 2018 Nov 28; 17(1). PMID: 30477520    Free PMC article.
Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum?
Dmitriy Zamarin.
Mol Ther, 2019 Oct 07; 27(11). PMID: 31586519    Free PMC article.
Foxp3 Post-translational Modifications and Treg Suppressive Activity.
Guoping Deng, Xiaomin Song, +3 authors, Mark I Greene.
Front Immunol, 2019 Nov 05; 10. PMID: 31681337    Free PMC article.
TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
Matthew J Reilley, Brittany Morrow, +3 authors, Michael A Curran.
J Immunother Cancer, 2019 Nov 28; 7(1). PMID: 31771649    Free PMC article.
Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer.
Lefu Huang, Guoliang Qiao, +6 authors, Herbert K Lyerly.
Oncol Lett, 2019 Dec 04; 18(6). PMID: 31788044    Free PMC article.
IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development.
Amy Li, Rebecca H Herbst, +15 authors, Tyler Jacks.
Cell Rep, 2019 Dec 05; 29(10). PMID: 31801068    Free PMC article.
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.
Haiping Wang, Fabien Franco, +17 authors, Ping-Chih Ho.
Nat Immunol, 2020 Feb 19; 21(3). PMID: 32066953    Free PMC article.
Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery.
Kenta Narumi, Reina Miyakawa, +7 authors, Kazunori Aoki.
Sci Rep, 2019 Apr 05; 9(1). PMID: 30944344    Free PMC article.
TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion.
Naveen Sharma, Jean Vacher, James P Allison.
Proc Natl Acad Sci U S A, 2019 May 12; 116(21). PMID: 31076558    Free PMC article.
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.
Yu-Tzu Tai, Liang Lin, +10 authors, Kenneth C Anderson.
Leukemia, 2018 Aug 24; 33(2). PMID: 30135465    Free PMC article.
Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice.
Alexandra Francian, Shelby Namen, +3 authors, Max Kullberg.
Nanomedicine, 2018 Nov 13; 18. PMID: 30419362    Free PMC article.
Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity.
Ole Audun Werner Haabeth, Timothy R Blake, +5 authors, Ronald Levy.
Cancer Res, 2019 Jan 30; 79(7). PMID: 30692215    Free PMC article.
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response.
Anu Sharma, Sumit K Subudhi, +5 authors, Padmanee Sharma.
Clin Cancer Res, 2019 Jun 05; 25(11). PMID: 31160495    Free PMC article.
PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity.
Martin W LaFleur, Thao H Nguyen, +9 authors, Arlene H Sharpe.
Nat Immunol, 2019 Sep 19; 20(10). PMID: 31527834    Free PMC article.
Development and characterization of mammary intraductal (MIND) spontaneous metastasis models for triple-negative breast cancer in syngeneic mice.
Xu-Liang Luo, Lan Lin, +5 authors, Yuan-Qiao He.
Sci Rep, 2020 Mar 15; 10(1). PMID: 32170125    Free PMC article.
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment.
Heidi Harjunpää, Marc Llort Asens, Carla Guenther, Susanna C Fagerholm.
Front Immunol, 2019 Jun 25; 10. PMID: 31231358    Free PMC article.
Highly Cited. Review.
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
Ingrid Teige, Linda Mårtensson, Björn L Frendéus.
Front Immunol, 2019 Apr 02; 10. PMID: 30930905    Free PMC article.
Tumor Targeted Nanocarriers for Immunotherapy.
Alejandro Baeza.
Molecules, 2020 Apr 01; 25(7). PMID: 32225049    Free PMC article.
New pathways in immune stimulation: targeting OX40.
Carolina Alves Costa Silva, Francesco Facchinetti, Bertrand Routy, Lisa Derosa.
ESMO Open, 2020 May 12; 5(1). PMID: 32392177    Free PMC article.
Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
Susumu Suzuki, Tetsuya Ogawa, +7 authors, Toyonori Tsuzuki.
Cancer Sci, 2020 Apr 19; 111(6). PMID: 32304268    Free PMC article.
Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies.
Lambros Tselikas, Thierry de Baere, +9 authors, Aurélien Marabelle.
J Immunother Cancer, 2020 Jun 24; 8(1). PMID: 32571995    Free PMC article.
Advances in targeted therapy for malignant lymphoma.
Li Wang, Wei Qin, +5 authors, Wei-Li Zhao.
Signal Transduct Target Ther, 2020 Apr 17; 5(1). PMID: 32296035    Free PMC article.
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Jonathan P O Hebb, Adriane R Mosley, +4 authors, Dean W Felsher.
Cancer Immunol Immunother, 2017 Sep 15; 67(1). PMID: 28905118    Free PMC article.
Combinatorial approach to cancer immunotherapy: strength in numbers.
Anna E Vilgelm, Douglas B Johnson, Ann Richmond.
J Leukoc Biol, 2016 Jun 04; 100(2). PMID: 27256570    Free PMC article.
A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system.
Aude Burlion, Rodrigo N Ramos, +7 authors, Gilles Marodon.
Oncoimmunology, 2019 May 31; 8(7). PMID: 31143518    Free PMC article.
OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.
Yayi He, Xiaoshen Zhang, +6 authors, Caicun Zhou.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555511    Free PMC article.
Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis.
Ane Ruiz-de-Angulo, Marc Bilbao-Asensio, +7 authors, Juan C Mareque-Rivas.
iScience, 2020 Sep 13; 23(9). PMID: 32919370    Free PMC article.
The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure.
Tianlin Zhou, Jinrong Peng, +7 authors, Zhiyong Qian.
Bioact Mater, 2020 Oct 03; 6(3). PMID: 33005832    Free PMC article.
T-cell agonists in cancer immunotherapy.
Yeonjoo Choi, Yaoyao Shi, +3 authors, Joud Hajjar.
J Immunother Cancer, 2020 Oct 07; 8(2). PMID: 33020242    Free PMC article.
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade.
Weilei Hu, Guosheng Wang, +2 authors, Ming You.
iScience, 2020 Oct 22; 23(10). PMID: 33083746    Free PMC article.
Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.
Chi Ma, Miaojun Han, +20 authors, Tim F Greten.
Science, 2018 May 26; 360(6391). PMID: 29798856    Free PMC article.
Highly Cited.
An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer.
Dilara Sahin, Natalia Arenas-Ramirez, +5 authors, Onur Boyman.
Nat Commun, 2020 Dec 24; 11(1). PMID: 33353953    Free PMC article.
Modulating the Tumour Microenvironment by Intratumoural Injection of Pattern Recognition Receptor Agonists.
Olivia K Burn, Kef K Prasit, Ian F Hermans.
Cancers (Basel), 2020 Dec 24; 12(12). PMID: 33352882    Free PMC article.
Harnessing innate immunity in cancer therapy.
Olivier Demaria, Stéphanie Cornen, +3 authors, Eric Vivier.
Nature, 2019 Oct 04; 574(7776). PMID: 31578484
Highly Cited. Review.
Domain binding and isotype dictate the activity of anti-human OX40 antibodies.
Jordana Griffiths, Khiyam Hussain, +18 authors, Mark S Cragg.
J Immunother Cancer, 2021 Jan 12; 8(2). PMID: 33428585    Free PMC article.
Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients.
Izhar S Batth, Long Dao, +11 authors, Shulin Li.
Int J Cancer, 2020 Jun 09; 147(12). PMID: 32506485    Free PMC article.
Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity.
Airi Harui, Sandra M McLachlan, +2 authors, Michael D Roth.
Cancer Immunol Immunother, 2020 Apr 26; 69(9). PMID: 32333082
Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy.
Helena Van Damme, Bruno Dombrecht, +26 authors, Jo Agnes Van Ginderachter.
J Immunother Cancer, 2021 Feb 17; 9(2). PMID: 33589525    Free PMC article.
Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy.
Kim M van Pul, Marieke F Fransen, Rieneke van de Ven, Tanja D de Gruijl.
Front Immunol, 2021 Mar 19; 12. PMID: 33732264    Free PMC article.
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy.
Navid Sobhani, Dana Rae Tardiel-Cyril, +3 authors, Yong Li.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33809974    Free PMC article.
In vivo NIR-II structured-illumination light-sheet microscopy.
Feifei Wang, Zhuoran Ma, +6 authors, Hongjie Dai.
Proc Natl Acad Sci U S A, 2021 Feb 03; 118(6). PMID: 33526701    Free PMC article.
OX40 as a novel target for the reversal of immune escape in colorectal cancer.
Lin-Hai Yan, Xiao-Liang Liu, +3 authors, Wei-Zhong Tang.
Am J Transl Res, 2021 Apr 13; 13(3). PMID: 33841630    Free PMC article.
Emerging strategies for treating metastasis.
Mark Esposito, Shridar Ganesan, Yibin Kang.
Nat Cancer, 2021 Apr 27; 2(3). PMID: 33899000    Free PMC article.
Recruitment and Expansion of Tregs Cells in the Tumor Environment-How to Target Them?
Justine Cinier, Margaux Hubert, +5 authors, Christine Ménétrier-Caux.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33924428    Free PMC article.
Intratumoural administration and tumour tissue targeting of cancer immunotherapies.
Ignacio Melero, Eduardo Castanon, +2 authors, Aurelien Marabelle.
Nat Rev Clin Oncol, 2021 May 20; 18(9). PMID: 34006998    Free PMC article.
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
Alexa C Glencer, Jasmine M Wong, +7 authors, Michael J Campbell.
NPJ Breast Cancer, 2021 May 27; 7(1). PMID: 34035311    Free PMC article.
Immune Responses against Disseminated Tumor Cells.
Ling Peng, Yongchang Zhang, Zibing Wang.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34063848    Free PMC article.
The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma.
Zhimei Zhou, Liteng Lin, +6 authors, Kangshun Zhu.
J Hepatocell Carcinoma, 2021 Jun 18; 8. PMID: 34136421    Free PMC article.
Non-cationic Material Design for Nucleic Acid Delivery.
Ziwen Jiang, S Thayumanavan.
Adv Ther (Weinh), 2020 Mar 01; 3(3). PMID: 34164572    Free PMC article.
Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma.
Xiaoru Sun, Lu Wang, +7 authors, Fuzhong Xue.
Aging (Albany NY), 2021 Jun 17; 13(12). PMID: 34133324    Free PMC article.
Sphingosine-1-phosphate Receptor-1 Agonist Averts the De Novo Generation of Autoreactive T-cells in Murine Acute Graft-versus-Host Disease.
Madeleine Vollmer, Philip Smith, +2 authors, Lukas T Jeker.
Hemasphere, 2021 Jul 16; 5(8). PMID: 34263142    Free PMC article.
Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights.
Marieke F Fransen, Thorbald van Hall, Ferry Ossendorp.
Int J Mol Sci, 2021 Sep 11; 22(17). PMID: 34502307    Free PMC article.
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology.
Karen A Autio, Valentina Boni, Rachel W Humphrey, Aung Naing.
Clin Cancer Res, 2019 Oct 12; 26(5). PMID: 31601568    Free PMC article.
Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy.
Luya Cai, Xuedan Du, +11 authors, Wenfeng Li.
Cancer Immunol Immunother, 2021 Nov 04; 71(7). PMID: 34731284
Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models.
Alexander A Pieper, Luke M Zangl, +17 authors, Zachary S Morris.
Front Immunol, 2021 Dec 07; 12. PMID: 34868010    Free PMC article.
Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop.
Francesco Marangoni, Ademi Zhakyp, +10 authors, Thorsten R Mempel.
Cell, 2021 Jun 23; 184(15). PMID: 34157302    Free PMC article.
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Nicola J Mason, Nicholas Chester, +6 authors, Don L Siegel.
MAbs, 2021 Dec 04; 13(1). PMID: 34856888    Free PMC article.
Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment.
Takashi Watanabe.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008305    Free PMC article.
Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment.
Yushuai Liu, Yuanyuan Geng, +3 authors, Honglin Jin.
Front Immunol, 2022 Feb 04; 12. PMID: 35111169    Free PMC article.
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.
Monika Semmrich, Jean-Baptiste Marchand, +15 authors, Björn Frendéus.
J Immunother Cancer, 2022 Jan 22; 10(1). PMID: 35058324    Free PMC article.
LIMK2 Is a Novel Prognostic Biomarker and Correlates With Tumor Immune Cell Infiltration in Lung Squamous Cell Carcinoma.
Yongcheng Su, Beibei Xu, +3 authors, Tianhui Hu.
Front Immunol, 2022 Mar 12; 13. PMID: 35273591    Free PMC article.
Cell-mediated immune resistance in cancer.
Yuhao Wang, Emily Hays, Martina Rama, Benjamin Bonavida.
Cancer Drug Resist, 2020 Jan 01; 3(2). PMID: 35310881    Free PMC article.
Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies.
Oliver Kepp, Aurelien Marabelle, Laurence Zitvogel, Guido Kroemer.
Nat Rev Clin Oncol, 2019 Oct 09; 17(1). PMID: 31595049
Improving cancer immunotherapy through nanotechnology.
Michael S Goldberg.
Nat Rev Cancer, 2019 Sep 08; 19(10). PMID: 31492927
Highly Cited. Review.
Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma.
Heng Ma, Peng-Hui Feng, +3 authors, Jie Chen.
BMC Cancer, 2022 May 14; 22(1). PMID: 35562682    Free PMC article.